Peripheral hematopoietic stem cell mobilization utilizing growth factors in donors with sickle cell trait is safe and effective

Damlaj, Moussab; Alaskar, Ahmed; Ghazi, Samer; Alahmari, Bader; Alhejazi, Ayman; Alzahrani, Mohsen

doi:10.1038/s41409-018-0208-3

Cited by 3 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, the intensified G‐CSF PBSC mobilization was well tolerated and none of the SCT donor has experienced unexpected adverse events compared to healthy donors, including symptoms resembling SC‐related complications. The observed findings do not differ with regard to adverse effects and use of analgesics under G‐CSF mobilization compared to various previously reported studies in healthy donors 22,24,30,31 …”

Section: Discussionsupporting

confidence: 45%

“…The observed findings do not differ with regard to adverse effects and use of analgesics under G-CSF mobilization compared to various previously reported studies in healthy donors. 22,24,30,31 Although there are no guidelines or recommendations, there are suggestions to avoid G-CSF based mobilization of peripheral stem cells in SCT donors with HbS levels over 30% or a leukocytosis over 80 Â 10 9 /L. 19,23,25 We observed in our SCT patient cohort with a median HbS of 38% (range 25%-41%) and leukocyte counts of up to 80 Â 10 9 /L no symptoms resembling sickle cell crisis.…”

Section: Adverse Eventsmentioning

confidence: 69%

“…At present, exist no study of severe SCD like complications in SCT patients after G‐CSF mobilization. However, there are various reports of successful G‐CSF stem cell mobilizations from SCT individuals with no significant SCD‐like complications 23–25,30 . Only in the prospective study of Kang et al, it was reported that after G‐CSF mobilization in eight SCT donors, the cumulative symptom score was significantly higher with a trend toward higher use of analgesia as compared to healthy donors 24 .…”

Section: Discussionmentioning

confidence: 99%

“…However, there are various reports of successful G-CSF stem cell mobilizations from SCT individuals with no significant SCD-like complications. [23][24][25]30 Only in the prospective study of Kang et al, it was reported that after G-CSF mobilization in eight SCT donors, the cumulative symptom score was significantly higher with a trend toward higher use of analgesia as compared to healthy donors. 24 The intensified G-CSF regimen with increased G-CSF dosage at the end of the mobilization regimen that was used in our SCT donors is based on previous studies mostly with African American SCT donors.…”

Section: Adverse Eventsmentioning

confidence: 99%

See 3 more Smart Citations

Feasibility of peripheral blood stem cell collection from sickle cell trait donors with an intensified G‐CSF regimen

Mohrez,

Troeger,

Kleinschmidt

et al. 2023

European J of Haematology

View full text Add to dashboard Cite

ObjectivesAllogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment for SCD and bone marrow from an HLA‐matched sibling is currently the standard of care. Haploidentical HSCT from a family donor with a TCR αβ/CD19 depleted graft (T‐haplo) is an increasingly successful alternative, which requires the generation of G‐CSF stimulated peripheral stem cell (PBSC) from haploidentical relatives. These sickle cell trait (SCT) donors reported to develop SCD‐related complications in conditions of severe stress.MethodsIn this retrospective analysis, we compared the safety and efficacy of PBSC mobilization with a G‐CSF intensified mobilization regimen in SCT donors with a conventional G‐CSF mobilization regimen in healthy donors.ResultsThe reported adverse events were similar during intensified G‐CSF mobilization, apheresis, and shortly after stem cell apheresis in SCT and control donors. In SCT and control donors, we were able to mobilize high yields of CD34+ stem cells and the harvested CD34+ cell count was comparable with control donors.ConclusionsPeripheral stem cell mobilization using an intensified G‐CSF regimen is safe, and well tolerated among SCT donors. SCT donors are a valid alternative for collection of peripheral CD34+ stem cells for T‐cell‐depleted haploidentical stem cell transplantation.

show abstract

Section: Discussionsupporting

confidence: 45%

Section: Adverse Eventsmentioning

confidence: 69%

Section: Discussionmentioning

confidence: 99%

Section: Adverse Eventsmentioning

confidence: 99%

See 2 more Smart Citations

Feasibility of peripheral blood stem cell collection from sickle cell trait donors with an intensified G‐CSF regimen

Mohrez,

Troeger,

Kleinschmidt

et al. 2023

European J of Haematology

View full text Add to dashboard Cite

show abstract

“…A total of 116 (58%) donors had sickle cell trait and underwent GCSF mobilization without major adverse events (AEs) as previously reported. 15 Nineteen (10%) and 23 (11%) had major and minor ABO incompatibility, respectively. TBI was given on day À1 in 57 (29%) and day À2 in the remaining 143 (71%).…”

Section: Transplant Characteristicsmentioning

confidence: 99%

Favorable outcome of non‐myeloablative allogeneic transplantation in adult patients with severe sickle cell disease: A single center experience of 200 patients

Damlaj,

Alahmari,

Alaskar

et al. 2024

American J Hematol

Self Cite

View full text Add to dashboard Cite

Allogeneic hematopoietic stem cell transplant (HSCT) for adults with severe sickle cell disease (SCD) is potentially curative but not commonly utilized therapy due to complications such as graft failure (GF) and organ toxicity. Herein, we are reporting our long‐term outcome data of non‐myeloablative (NMA) HSCT in adults with severe SCD with emphasis on factors predicting event free survival (EFS). Adults with severe SCD undergoing NMA match‐related donor allogeneic HSCT from 2015 to 2021 with at least 12 months of follow‐up were included. A total of 200 patients were included with a median age of 26 years (14–43) and 56% were male. The median infused CD34 dose was 13.7 (5.07–25.8), respectively. Median absolute neutrophil count engraftment was 19 (13–39) days with 51% of patients receiving GCSF to expedite recovery. A total of 17 patients experienced GF; 3 as primary and 14 as secondary within a median time of 204 days (40–905). A 76% successfully discontinued sirolimus at the last follow‐up. Median follow‐up for the cohort is 29.2 (2.1–71.4) months. Estimated 3‐year EFS and OS were 88.2% (81.9–92.5) and 94.6% (89.2–97.3). At multivariable analysis, minor ABC incompatibility hazard ratio (HR) 4 (1.3–12.1; 0.014) and allo‐antibody against non‐ABO donor antigens HR 4.3 (1.3–14.1; 0.016) were significant for EFS. No clonal evolution or myeloid malignancies were seen. This largest single‐center report of NMA HSCT in adults with severe SCD further delineated its feasibility, potential toxicities, and fertility outcomes. GF remains a major impediment and appears dependent on ABO matching and non‐ABO antibodies.

show abstract

Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated following Allogeneic Transplantation in Patients with Sickle Cell Disease

Shah¹,

Bhoopatiraju²,

Abraham³

et al. 2022

Transplantation and Cellular Therapy

View full text Add to dashboard Cite

Peripheral hematopoietic stem cell mobilization utilizing growth factors in donors with sickle cell trait is safe and effective

Cited by 3 publications

References 9 publications

Feasibility of peripheral blood stem cell collection from sickle cell trait donors with an intensified G‐CSF regimen

Feasibility of peripheral blood stem cell collection from sickle cell trait donors with an intensified G‐CSF regimen

Favorable outcome of non‐myeloablative allogeneic transplantation in adult patients with severe sickle cell disease: A single center experience of 200 patients

Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated following Allogeneic Transplantation in Patients with Sickle Cell Disease

Contact Info

Product

Resources

About